LARIMAR THERAPEUTICS, INC. Shareholders' Equity
LARIMAR THERAPEUTICS, INC. (LRMR) had Shareholders' Equity of $127.38 million as of 2026-06-30, per its 10-Q filed 2026-08-04.
Financial Statements › Balance Sheet › Equity › Equity, Attributable to Parent
us-gaap:StockholdersEquity · last filed 2026-08-04
- 2026-06-30: Stockholders' Equity Attributable to Parent $127.38M.
- 2026-03-31: Stockholders' Equity Attributable to Parent $158.03M.
- 2025-12-31: Stockholders' Equity Attributable to Parent $78.08M.
- 2025-09-30: Stockholders' Equity Attributable to Parent $139.04M.
| Period end | Stockholders' Equity Attributable to Parent | Stockholders' Equity Attributable to Parent as first filed |
|---|---|---|
| 2026-06-30 | $127.38M 10-Q · filed 2026-08-04 | |
| 2026-03-31 | $158.03M 10-Q · filed 2026-08-04 | |
| 2025-12-31 | $78.08M 10-Q · filed 2026-08-04 | |
| 2025-09-30 | $139.04M 10-Q · filed 2025-11-05 | |
| 2025-06-30 | $119.85M 10-Q · filed 2026-08-04 | |
| 2025-03-31 | $144.27M 10-Q · filed 2026-08-04 | |
| 2024-12-31 | $171.81M 10-Q · filed 2026-08-04 | |
| 2024-09-30 | $198.40M 10-Q · filed 2025-11-05 | |
| 2024-06-30 | $211.40M 10-Q · filed 2025-11-05 | |
| 2024-03-31 | $230.84M 10-Q · filed 2025-11-05 | |
| 2023-12-31 | $81.72M 10-K · filed 2026-03-19 | |
| 2023-09-30 | $92.71M 10-Q · filed 2024-10-30 | |
| 2023-06-30 | $99.93M 10-Q · filed 2024-10-30 | |
| 2023-03-31 | $106.24M 10-Q · filed 2024-10-30 | |
| 2022-12-31 | $110.90M 10-K · filed 2025-03-24 | |
| 2022-09-30 | $118.66M 10-Q · filed 2023-11-14 | |
| 2022-06-30 | $50.06M 10-Q · filed 2023-11-14 | |
| 2022-03-31 | $57.10M 10-Q · filed 2023-11-14 | |
| 2021-12-31 | $64.41M 10-K · filed 2024-03-14 | |
| 2021-09-30 | $72.07M 10-Q · filed 2022-11-10 | |
| 2021-06-30 | $67.53M 10-Q · filed 2022-11-10 | |
| 2021-03-31 | $78.78M 10-Q · filed 2022-11-10 | |
| 2020-12-31 | $89.69M 10-K · filed 2023-03-14 | |
| 2020-09-30 | $102.64M 10-Q · filed 2021-11-12 | |
| 2020-06-30 | $112.54M 10-Q · filed 2021-11-12 | |
| 2020-03-31 | $2.26M 10-Q · filed 2021-11-12 | $50.74M 10-Q · filed 2020-05-07 |
| 2019-12-31 | -$694.00K 10-K · filed 2022-03-25 | $53.62M 10-K · filed 2020-03-05 |
| 2019-09-30 | $1.90M 10-Q · filed 2020-11-12 | $59.88M 10-Q · filed 2019-11-06 |
| 2019-06-30 | $543.00K 10-Q · filed 2020-11-12 | $72.14M 10-Q · filed 2019-08-08 |
| 2019-03-31 | $1.22M 10-Q · filed 2020-11-12 | $82.36M 10-Q · filed 2019-05-09 |
| 2018-12-31 | $2.91M 10-K · filed 2021-03-04 | $93.27M 10-K · filed 2019-03-14 |
| 2018-09-30 | $103.94M 10-Q · filed 2019-11-06 | |
| 2018-06-30 | $52.02M 10-Q · filed 2019-11-06 | |
| 2018-03-31 | $65.00M 10-Q · filed 2019-11-06 | |
| 2017-12-31 | $78.22M 10-K · filed 2020-03-05 | |
| 2017-09-30 | $89.23M 10-Q · filed 2017-11-07 | |
| 2017-06-30 | $99.63M 10-Q · filed 2017-08-09 | |
| 2017-03-31 | $110.77M 10-Q · filed 2017-05-09 | |
| 2016-12-31 | $121.73M 10-K · filed 2020-03-05 | |
| 2016-09-30 | $130.17M 10-Q · filed 2016-11-09 | |
| 2016-06-30 | $142.24M 10-Q · filed 2016-08-05 | |
| 2016-03-31 | $154.43M 10-Q · filed 2016-05-10 | |
| 2015-12-31 | $169.11M 10-K · filed 2019-03-14 | |
| 2015-09-30 | $189.70M 10-Q · filed 2015-11-13 | |
| 2015-06-30 | $206.19M 10-Q · filed 2015-08-14 | |
| 2015-03-31 | $221.67M 10-Q · filed 2015-05-14 | |
| 2014-12-31 | $104.44M 10-K · filed 2018-03-09 | |
| 2014-09-30 | $111.20M 10-Q · filed 2014-11-13 | |
| 2014-06-30 | $125.42M 10-Q · filed 2014-08-14 | |
| 2013-12-31 | -$68.57M 10-K · filed 2017-03-10 | |
| 2012-12-31 | -$54.73M 10-K · filed 2016-03-15 | |
| 2011-12-31 | -$40.92M 10-K · filed 2015-03-25 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Emergent BioSolutions Inc. (EBS) | United States | $0.347B | -2.43 |
| ENANTA PHARMACEUTICALS INC (ENTA) | United States | $0.349B | -6.72 |
| Benitec Biopharma Inc. (BNTC) | United States | $0.337B | -10.08 |
| BioAge Labs, Inc. (BIOA) | United States | $0.333B | -11.88 |
| Vogenx, Inc. (VOGX) | United States | $0.355B | |
| BridgeBio Oncology Therapeutics, Inc. (BBOT) | United States | $0.320B | -3.35 |
| Evommune, Inc. (EVMN) | United States | $0.320B | -5.10 |
| Prelude Therapeutics Inc (PRLD) | United States | $0.318B | -7.01 |
| ABEONA THERAPEUTICS INC. (ABEO) | United States | $0.312B | -5.63 |
| GT Biopharma, Inc. (GTBP) | United States | $0.309B | -4.58 |